CLINICAL TRIALS PROFILE FOR OMNICEF
✉ Email this page to a colleague
All Clinical Trials for OMNICEF
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00644774 ↗ | A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications | Completed | Abbott | Phase 4 | 2003-01-01 | To compare the taste and smell acceptability of cefdinir (Omnicef) antibiotic suspension and azithromycin (Zithromax) antibiotic suspension following a single dose of each medication. |
| NCT00644891 ↗ | Pediatric Taste Test Study of Cefdinir (Omnicef) Versus Amoxicillin Antibiotic Suspension Medications | Completed | Abbott | Phase 4 | 2003-01-01 | To compare the taste and smell acceptability scores of cefdinir (Omnicef) versus amoxicillin oral antibiotic suspension medications in pediatric subjects. It was designed to determine if Omnicef or amoxicillin is preferred to the other with regard to taste or smell. |
| NCT00644943 ↗ | A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media | Completed | Abbott | Phase 4 | 2003-02-01 | The primary objective is to compare the safety and efficacy of cefdinir oral suspension, 7 mg/kg/day ql2hrs for 5 days, to amoxicillin/clavulanate oral suspension 45 mg/kg/day (based on amoxicillin component), in divided doses, q12h for 10 days, in children between 6 months and 6 years of age, with AOM. |
| NCT00645073 ↗ | Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis | Completed | Abbott | Phase 4 | 2003-11-01 | To compare the safety and efficacy of a ten-day course of therapy of cefdinir, 600 mg QD, to a ten-day course of therapy of levofloxacin, 500 mg QD, in the treatment of acute bacterial sinusitis. |
| NCT00645112 ↗ | A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media | Completed | Abbott | Phase 4 | 2003-11-01 | To compare the safety and efficacy of cefdinir oral suspension, 7 mg/kg every 12 hours for 5 days, to azithromycin oral suspension 10 mg/kg/day (Day 1) then 5 mg/kg/day (Days 2-5) for a total of 5 days, in children between 6 months and 6 years of age, with AOM. |
| NCT00645125 ↗ | A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications | Completed | Abbott | Phase 4 | 2003-01-01 | To compare the taste and smell acceptability scores of cefdinir (Omnicef) versus amoxicillin oral antibiotic suspension medications in pediatric subjects. It is designed to determine if Omnicef or amoxicillin is preferred to the other with regard to taste or smell. |
| NCT00834535 ↗ | Cefdinir Capsules 300 mg, Non-fasting | Completed | Teva Pharmaceuticals USA | Phase 1 | 2005-07-01 | This study will compare the relative bioavailability (rate and extent of absorption) of 300 mg Cefdinir Capsules manufactured and distributed by TEVA pharmaceuticals USA with that of OMNICEF® Capsules by CEPH International Corporation for Abbott Laboratories following a single oral dose (1 x 300mg capsule) in healthy adult subjects administered under non-fasting conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OMNICEF
Condition Name
Clinical Trial Locations for OMNICEF
Trials by Country
Clinical Trial Progress for OMNICEF
Clinical Trial Phase
Clinical Trial Sponsors for OMNICEF
Sponsor Name
